# NKGen Biotech, Inc.

NKGen Biotech, Inc. is a company headquartered in Santa Ana, CA, United States.

## Company overview

- **Legal name:** NKGen Biotech, Inc.
- **Former names in filing history:** Graf Acquisition Corp. IV (2021-02-23 to 2023-09-29)
- **Classification:** Company
- **Industry (SIC):** 2836 — Biological Products, (No Diagnostic Substances)
- **Headquarters:** Santa Ana, CA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001845459

## About

NKGen Biotech, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001845459, and its reported industry is Biological Products, (No Diagnostic Substances). In 10-K filed on 2025-10-08, it reported net income of USD -44,286,000; total assets of USD 16,231,000 for the fiscal period ended 2024-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2024 (period ended 2024-12-31)

- **Net income:** -$44.3M (USD -44,286,000)
- **Total assets:** $16.2M (USD 16,231,000)
- **Cash and equivalents:** $106,000 (USD 106,000)
- **Operating cash flow:** -$20.9M (USD -20,881,000)

### FY2023 (period ended 2023-12-31)

- **Revenue:** $0 (USD 0)
- **Net income:** -$83.0M (USD -82,954,000)
- **Total assets:** $16.5M (USD 16,481,000)
- **Cash and equivalents:** $26,000 (USD 26,000)
- **Operating cash flow:** -$21.9M (USD -21,948,000)

### FY2022 (period ended 2022-12-31)

- **Net income:** $4.5M (USD 4,548,351)
- **Total assets:** $174.4M (USD 174,366,108)
- **Cash and equivalents:** $635,155 (USD 635,155)
- **Operating cash flow:** -$1.6M (USD -1,570,993)
- **Later filings:** Net income, Total assets, Cash and equivalents, Operating cash flow: shown as originally filed; later filings report different values for the same periods.

## Recent SEC filings

- Form 8-K — filed 2026-09-02 — period 2026-08-05 — CURRENT REPORT
- Form 8-K — filed 2026-07-17 — period 2026-07-13 — CURRENT REPORT
- Form 8-K — filed 2026-06-02 — period 2026-05-27 — CURRENT REPORT
- Form 8-K — filed 2026-05-21 — period 2026-05-15 — CURRENT REPORT
- Form 8-K — filed 2026-05-04 — period 2026-04-28 — CURRENT REPORT
- Form 8-K — filed 2026-04-21 — period 2026-04-15 — CURRENT REPORT
- Form 8-K — filed 2026-02-26 — period 2026-02-20 — CURRENT REPORT
- Form 8-K — filed 2026-02-05 — period 2026-01-30 — CURRENT REPORT
- Form 8-K — filed 2026-01-26 — period 2026-01-20 — CURRENT REPORT
- Form 10-Q — filed 2026-01-20 — period 2025-03-31 — 10-Q
- Form 8-K — filed 2026-01-16 — period 2026-01-12 — CURRENT REPORT
- Form 8-K — filed 2026-01-09 — period 2026-01-05 — CURRENT REPORT

---

Updated: 2026-10-23T19:32:55Z

Canonical page: https://altss.com/profile/nkgen-biotech-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology